3138-90-7

Usage

Uses

Used in Pharmaceutical Industry:
1-Benzyl-3-methylpiperazine is used as a chemical intermediate for the preparation of piperazinylpyrimidines, which are known for their tranquilizing effects. 1-Benzyl-3-methylpiperazine plays a crucial role in the synthesis of these tranquilizers, contributing to the development of medications that help alleviate anxiety and stress.
As a colorless liquid, 1-Benzyl-3-methylpiperazine also has potential applications in other industries, such as in the formulation of various chemical products or as a component in research and development for new pharmaceutical compounds. However, the primary use of 1-Benzyl-3-methylpiperazine is in the pharmaceutical industry for the development of tranquilizers.

InChI:InChI=1/C12H18N2/c1-11-9-14(8-7-13-11)10-12-5-3-2-4-6-12/h2-6,11,13H,7-10H2,1H3

Upstream product

• 78-98-8 2-oxopropanal 
• 4152-09-4 N-benzylethylenediamine 
• 109-07-9 (RS)-2-methylpiperazine 
• 98-88-4 benzoyl chloride 
• 584-08-7 potassium carbonate 
• 100-44-7 benzyl chloride 

Downstream Products

• 80827-71-0 8-[4-(2-Methyl-4-[phenylmethyl]-1-piperazinyl)-butyl]-8-azaspiro[4.5]decane-7,9-dione 
• 314729-19-6 4-benzyl-2-methyl-1-propionylpiperazine 
• 314729-17-4 4-benzyl-1-(4-fluorobenzenesulfonyl)-2-methylpiperazine 
• 120737-77-1 tert-butyl 2-methyl-4-benzyl-1-piperazinecarboxylate 
• 314729-18-5 1-benzoyl-4-benzyl-2-methylpiperazine 
• 120737-78-2 tert-butyl 2-methylpiperazine-1-carboxylate 
• 1346681-91-1 benzyl (R)-4-benzyl-2-methylpiperazine-1-carboxylate 
• 1417826-87-9 (S)-1-(4-benzyl-2-methylpiperazin-1-yl)-3-phenylpropan-1-one 
• 132871-11-5 (R)-3-Methyl-1-(phenylmethyl)piperazine 
• 1391602-61-1 (4-benzyl-2-methyl-piperazin-1-yl)-pyrrolidin-1-yl-methanone 
• 1346681-92-2 (S)-4-benzyl-1-(3-mesitylpropanoyl)-2-methylpiperazine 
• 313657-09-9 3-Chloro-2-(4-benzyl-2-methyl-1-piperazinyl)pyrazine 

Relevant academic research and scientific papers

Biocatalytic Access to Piperazines from Diamines and Dicarbonyls

Given the widespread importance of piperazines as building blocks for the production of pharmaceuticals, an efficient and selective synthesis is highly desirable. Here we show the direct synthesis of piperazines from 1,2-dicarbonyl and 1,2-diamine substrates using the R-selective imine reductase from Myxococcus stipitatus as biocatalyst. Various N- and C-substituted piperazines with high activity and excellent enantioselectivity were obtained under mild reaction conditions reaching up to 8.1 g per liter.

Design, synthesis, and biological evaluation of novel 2-methylpiperazine derivatives as potent CCR5 antagonists

Three series of novel 2-methylpiperazine derivatives were designed and synthesized using a fragment-assembly strategy. Among them, six compounds (13, 16, 18, 22, 33, and 36) showed potent activity against CCR5 comparable to that of the positive control, maraviroc, in calcium mobilization assay. Moreover, some compounds were selected and further tested for their antiviral activity in HIV-1 single cycle assay. As a result, four compounds (13, 16, 33, and 36) showed antiviral activity at the nanomolar level. Additionally, the potent four compounds showed no cytotoxicity at a concentration of 10 μM.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS

The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.

1,4-DISUBSTITUTED PIPERAZINE AND 1,4-DISUBSTITUTED AZEPANE AS 11 -BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS

Compounds of formula (I): wherein variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are described.

Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity

Several 4-substituted 1-acylpiperazines, obtained by molecular simplification of 4-substituted 1,4-diazabicyclo[4.3.0]nonan-9-ones, have been synthesized and tested in vivo on the mouse passive avoidance test, to evaluate their nootropic activity. The results show that, apparently, an N-acylpiperazine group can mimic the 2-pyrrolidinone ring of 1,4-diazabicyclo[4.3.0]nonan-9-one, as the compounds of the new series maintain high nootropic activity. Moreover molecular simplification produces more clear-cut structure-activity relationships with respect to the parent series. The mechanism of action also appears to be similar in the two series. In fact, although the molecular mechanism remains to be elucidated, the most potent compound of each class (DM232 and 13, DM235) is able to increase acetylcholine release in rat brain. Piperazine derivatives represent a new class of nootropic drugs with an in vivo pharmacological profile very similar to that of piracetam, showing much higher potency with respect to the reference compound. Among the compounds studied, 13 (DM235) shows outstanding potency, being active at a dose of 0.001 mg kg-1 sc.

7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics

Compound 1 (1-benzyl-3-methyl-4-[4-(4-fluorophenyl)-4- oxobutyl]piperazine), a synthetic intermediate identified as a potential atypical antipsychotic, was selected as the starting point for pharmacological improvement. From 1, sequential structural variations were conducted in order to improve its potency and oral bioavailability. These variations included a series of piperazine, ethanediamine, and piperidine derivatives. The piperidine series afforded some orally potent compounds in the inhibition of apomorphine-induced climbing and hyperactivity in mice, which are regarded as behavioral models predictive of antipsychotic efficacy. Further optimization of these structures led to the highly potent 7-[3-(1- piperidinyl)propoxy]chromenones. Inhibition of stereotypies and induction of catalepsy in rats at doses substantially higher than required for inhibition of climbing suggest an atypical antipsychotic profile, which is assumed to predict a reduced induction of extrapyramidal side effects in humans.

NEW THERAPEUTIC USE OF HETEROCYCLPIPERAZINES AS 5-HT3 AGONISTS AND NEW COMPOUNDS

New therapeutic use of some heterocyclylpiperazines of formula (I) STR1 wherein R represents hydrogen or (C 1-C 4)alkyl, R. sub. 1 represents hydrogen or a methyl group, R 2 represents hydrogen or a halogen atom; X et Y represent each--CH=, or one is--CH=